Accès ouvert

Anandamide in First-Episode Psychosis: Associations with Symptoms and Inflammation

Article scientifique 2026 Anglais

Résumé

Introduction Schizophrenia (SCZ) is a severe disorder with partially understood pathophysiology. The early stage is crucial for understanding pathogenic mechanisms and improving treatment strategies. Anandamide (AEA), a neurotransmitter of the endocannabinoid system, may be protective against psychosis. Objectives This study aimed to measure serum AEA levels in first-episode psychosis (FEP) at admission (T0) and remission (T1), compare them to healthy controls and explore clinical and inflammatory correlates of AEA levels Methods In a longitudinal observational study (Nov 2021–Dec 2023), 69 FEP patients and 74 controls underwent sociodemographic, clinical, psychometric assessment (PANSS, GAF, CGI, CAST) and blood tests (high sensitivity-CRP (hs-CRP), AEA, metabolic parameters). Results Patients were predominantly young, single men, with high unemployment; one-third used cannabis. At T0, AEA levels were significantly higher in patients than in controls (p = 0.045) and remained stable at T1. AEA showed consistent negative correlations with all PANSS subscales (e.g., total PANSS at T0: r = −0.45, p<0.001; T1: r = −0.41, p=0.034),and CGI-severity scale (At T0: r = −0.316, p = 0.008). Its elevation was independent of cannabis use, and its association with FEP persisted after adjustment (OR = 3.54, 95% CI = 1.32–9.46; p = 0.012). A positive correlation with hs-CRP was observed at T0 (r = 0.24, p = 0.048), independent of other confounding factors such as smoking and metabolic parameters. Conclusions AEA is elevated in FEP, inversely associated with symptom severity and positively correlated with inflammation, suggesting a potential neuroprotective and anti-inflammatory role. The endocannabinoid system may represent a promising target for novel therapeutic strategies. Disclosure of Interest None Declared

Citer ce document

Flah, W., Lansari, R., Kamoun, A., Ghazzani, I. (2026). Anandamide in First-Episode Psychosis: Associations with Symptoms and Inflammation. https://doi.org/10.1192/j.eurpsy.2026.10539

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Voir l'article sur le site de la revue

Statistiques

Consultations : 1

Téléchargements : 0